Advertisement

Characteristics of Lynch syndrome associated ovarian cancer

      Highlights

      • Ovarian cancer in women with LS develops at an early age, with a wide age-range of onset and at an early stage.
      • These LS associated ovarian cancers most often has an endometrioid or serous type histology with a good overall survival.
      • The early stage of ovarian cancer, in women with LS, could not be attributed to annual gynecological surveillance.

      Abstract

      Objective

      To describe clinical characteristics of Lynch syndrome associated ovarian cancer and the efficacy of surveillance in the early detection of these ovarian cancers.

      Methods

      All Lynch syndrome associated ovarian cancer cases identified in either the Dutch Lynch syndrome registry (DLSR) between 1987 and 2016, and/or the cohort at the University Medical Center Groningen (UMCG) between 1993 and 2016 were included. Clinical data on age at diagnosis, mutation type, histological type, FIGO stage, treatment, follow-up and gynecological surveillance were collected.

      Results

      A total of 46/798 (6%) women in the DLSR and 7/80 (9%) in the UMCG cohort were identified as LS associated ovarian cancer patients. The median age at ovarian cancer diagnosis was 46.0 years (range 20–75 years). The most frequently reported histological type was endometrioid adenocarcinoma (40%; n = 21) and serous carcinoma (36%; n = 19). Most tumors (87%; n = 46) were detected at an early stage (FIGO I/II). Forty-one of 53 (77%) patients were diagnosed with ovarian cancer before LS was diagnosed. In the other 12/53 (23%) women, ovarian cancer developed after starting annual gynecological surveillance for LS; three ovarian cancers were screen-detected in asymptomatic women. Overall survival was 83%.

      Conclusion

      Ovarian cancer in women with LS has a wide age-range of onset, is usually diagnosed at an early stage with predominantly endometrioid type histology and a good overall survival. The early stage at diagnosis could not be attributed to annual gynecological surveillance.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Aysal A.
        • Karnezis A.
        • Medhi I.
        • Grenert J.P.
        • Zaloudek C.J.
        • Rabban J.T.
        Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
        Am. J. Surg. Pathol. 2012; 36: 163-172
        • Walsh T.
        • Casadei S.
        • Lee M.K.
        • Pennil C.C.
        • Nord A.S.
        • Thornton A.M.
        • et al.
        Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
        Proc. Natl. Acad. Sci. U. S. A. 2011; 108: 18032-18037
        • Rubin S.C.
        • Blackwood M.A.
        • Bandera C.
        • Behbakht K.
        • Benjamin I.
        • Rebbeck T.R.
        • Boyd J.
        BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
        Am. J. Obstet. Gynecol. 1998; 178: 670-677
        • Pal T.
        • Permuth-Wey J.
        • Betts J.A.
        • Krischer J.P.
        • Fiorica J.
        • Arango H.
        • et al.
        BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
        Cancer. 2005; 104: 2807-2816
        • Walsh M.D.
        • Cummings M.C.
        • Buchanan D.D.
        • Dambacher W.M.
        • Arnold S.
        • McKeone D.
        • et al.
        Molecular, pathologic, and clinical features of early-onset endometrial cancer: identifying presumptive Lynch syndrome patients.
        Clin. Cancer Res. 2008; 14: 1692-1700
        • Lynch H.T.
        • Casey M.J.
        • Snyder C.L.
        • Bewtra C.
        • Lynch J.F.
        • Butts M.
        • et al.
        Hereditary ovarian carcinoma: heterogenity, molecular genetics, pathology and management.
        Mol. Oncol. 2009; 3: 97-137
        • Aarnio M.
        • Sankila R.
        • Pukkala E.
        • Salovaara R.
        • Aaltonen L.A.
        • de la Chapelle A.
        • et al.
        Cancer risk in mutation carriers of DNA-mismatch-repair genes.
        Int. J. Cancer. 1999; 81: 214-218
        • Barrow E.
        • Robinson L.
        • Alduaij W.
        • Shenton A.
        • Clancy T.
        • Lalloo F.
        • et al.
        Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations.
        Clin. Genet. 2009; 75: 141-149
        • Renkonen-Sinisalo L.
        • Butzow R.
        • Leminen A.
        • Lehtovirta P.
        • Mecklin J.P.
        • Jarvinen H.J.
        Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome.
        Int. J. Cancer. 2006; 120: 821
        • Senter L.
        • Clendenning M.
        • Sotamaa K.
        • Hampel H.
        • Green J.
        • Potter J.D.
        • et al.
        The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations.
        Gastroenterology. 2008; 135: 419-428
        • Moldovan R.
        • Keating S.
        • Clancy T.
        The impact of risk-reducing gynaecological surgery in premenopausal women at high risk of endometrial and ovarian cancer due to lynch syndrome.
        Familial Cancer. 2015; 14: 51-60
        • Vasen H.F.
        • Stormorken A.
        • Menko F.H.
        • Nagengast F.M.
        • Kleibeuker J.H.
        • Griffioen G.
        • et al.
        MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.
        J. Clin. Oncol. 2001; 19: 4074-4080
        • Watson P.
        • Vasen H.F.
        • Mecklin J.P.
        • Bernstein I.
        • Aarnio M.
        • Järvinen H.J.
        • et al.
        The risk of extra-colonic, extra-endometrial cancer in the lynch syndrome.
        Int. J. Cancer. 2008; 123: 444-449
        • Helder-Woolderink J.M.
        • Blok E.A.
        • Vasen H.F.A.
        • Hollema H.
        • Mourits M.J.
        • De Bock G.H.
        Ovarian cancer in Lynch syndrome; a systematic review.
        Eur. J. Cancer. 2016; 55: 65-73
        • Ryan N.A.J.
        • Evans D.G.
        • Green K.
        • Crosbie E.J.
        Pathological features and clinical behaviour of lynch syndrome-associated ovarian cancer.
        Gynecol. Oncol. 2017; 144: 491-495
        • Gerritzen L.H.M.
        • Hoogerbrugge N.
        • Oei A.L.
        • Nagengast F.M.
        • Van Ham M.A.
        • Massuger L.F.
        • et al.
        Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome.
        Familial Cancer. 2009; 8: 391-397
        • Helder-Woolderink J.M.
        • De Bock G.H.
        • Sijmons R.H.
        • Hollema H.
        • Mourits M.J.
        The additional value of endometrial sampling in the early detection of endometrial cancer in women with Lynch syndrome.
        Gynecol. Oncol. 2013; 131: 304-308
        • Stuckless S.
        • Green J.
        • Dawson L.
        • Barrett B.
        • Woods M.O.
        • Dicks E.
        • et al.
        Impact of gynecological screening in Lynch syndrome carriers with an MSH2 mutation.
        Clin. Genet. 2013; 83: 359-364
        • Jacobs I.J.
        • Skates S.J.
        • MacDonald N.
        • Menon U.
        • Rosenthal A.N.
        • Davies A.P.
        • et al.
        Screening for ovarian cancer: a pilot randomised controlled trial.
        Lancet. 1999; 353: 1207-1210
        • Hermsen B.B.
        • Olivier R.I.
        • Verheijen R.H.
        • van Beurden M.
        • de Hullu J.A.
        • Massuger L.F.
        • et al.
        No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study.
        Br. J. Cancer. 2007; 96: 1335-1342
        • Menon U.
        • Gentry-Maharaj A.
        • Hallett R.
        • Ryan A.
        • Burnell M.
        • Sharma A.
        • et al.
        Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
        Lancet Oncol. 2009; 10: 327-340
        • Velde van der N.M.
        • Mourits M.J.
        • Arts H.J.
        • de Vries J.
        • Leegte B.K.
        • Dijkhuis G.
        • et al.
        Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?.
        Int. J. Cancer. 2009; 124: 919-923
        • Buys S.S.
        • Partridge E.
        • Black A.
        • Johnson C.C.
        • Lamerato L.
        • Isaacs C.
        • et al.
        Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) Cancer screening randomized controlled trial.
        JAMA. 2011; 305: 2295-2303
        • Jacobs I.
        • Menon U.
        • Ryan A.
        • Gentry-Maharaj A.
        • Burnell M.
        • Kalsi J.K.
        • et al.
        Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial.
        Lancet. 2016; 387: 945-956
        • Watson P.
        • Bützow R.
        • Lynch H.T.
        • Mecklin J.P.
        • Järvinen H.J.
        • Vasen H.F.
        • et al.
        International collaborative group on HNPCC. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer.
        Gynecol. Oncol. 2001; 82: 223-228
        • Ketabi Z.
        • Bartuma K.
        • Bernstein I.
        • Malander S.
        • Grönberg H.
        • Björck E.
        • et al.
        Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors.
        Gynecol. Oncol. 2011; 121: 462-465
        • Niskakoski A.
        • Kaur S.
        • Renkonen-Sinisalo L.
        • Lassus H.
        • Järvinen H.J.
        • Mecklin J.P.
        • et al.
        Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas.
        Int. J. Cancer. 2013; 133: 2596-2608
      1. http://www.STOET.nl, accessed 10 April 2017.

      2. http://www.oncoline.nl/erfelijke darmkanker, 2015.

        • Grindedal E.M.
        • Blanco I.
        • Stormorken A.
        • Maehle L.
        • Clark N.
        • Gonzalez S.
        • et al.
        High risk of endometrial cancer in colorectal cancer kindred is pathognomonic for MMR mutation carriers.
        Familial Cancer. 2009; 8: 145-151
        • Mavaddat N.
        • Barrowdale D.
        • Andrulis I.L.
        • Domchek S.M.
        • Eccles D.
        • Nevanlinna H.
        • et al.
        Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA).
        Cancer Epidemiol. Biomark. Prev. 2012; 21: 134-147
        • Grindedal E.M.
        • Renkonen-Sinisalo L.
        • Vasen H.
        • Evans G.
        • Sala P.
        • Blanco I.
        • et al.
        Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds.
        J. Med. Genet. 2010; 47: 99-102
        • Risch H.A.
        • McLaughlin J.R.
        • David D.E.
        • Rosen B.
        • Bradley L.
        • Kwan E.
        • et al.
        Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
        Am. J. Hum. Genet. 2001; 68: 700-710
        • Bonadona V.
        • Bonaïti B.
        • Olschwang S.
        • Grandjouan S.
        • Huiart L.
        • Longy M.
        • et al.
        French cancer genetics network. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
        JAMA. 2011; 305: 2304-2310
        • Casey M.J.
        • Bewtra C.
        • Lynch H.T.
        • Snyder C.
        • Stacy M.
        • Watson P.
        Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
        Familial Cancer. 2013; 12: 719-740
        • Evans D.G.
        • Gaarenstroom K.N.
        • Stirling D.
        • Shenton A.
        • Maehle L.
        • Dørum A.
        • et al.
        Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers.
        J. Med. Genet. 2009; 46: 593-597
        • Huang R.L.
        • Chao C.F.
        • Ding D.C.
        • Yu C.P.
        • Chang C.C.
        • Lai H.C.
        • et al.
        Multiple epithelial and nonepithelial tumors in hereditary nonpolyposis colorectal cancer: characterization of germline and somatic mutations of the MSH2 gene and heterogeneity of replication error phenotypes.
        Cancer Genet. Cytogenet. 2004; 153: 108-114
        • Järvinen H.J.
        • Renkonen-Sinisalo L.
        • Aktán-Collán K.
        • Peltomäki P.
        • Aaltonen L.A.
        • Mecklin J.P.
        Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members.
        J. Clin. Oncol. 2009; 27: 4793-4797
        • Ketabi Z.
        • Gerdes A.M.
        • Mosgaard B.
        • Ladelund S.
        • Bernstein I.
        The results of gynecologic surveillance in families with hereditary nonpolyposis colorectal cancer.
        Gynecol. Oncol. 2014; 133: 526
        • Schmeler K.M.
        • Lynch H.T.
        • Chen L.M.
        • Munsell M.F.
        • Soliman P.T.
        • Clark M.B.
        • et al.
        Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.
        N. Engl. J. Med. 2006; 354: 261-269